SCHEMBL4356007

SCHEMBL4356007

O=C(Nc1ccc(OC(F)(F)F)cc1)Nc1cccc(F)c1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.66
STING1 Q86WV6 1/20 0.55
P2RY1 P47900 12/20 0.55
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
PKM P14618 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
FAAH O00519 1/20 0.53
MEN1 O00255 1/20 0.53
TP53 P04637 1/20 0.53
MAPT P10636 1/20 0.53
CASP3 P42574 1/20 0.53
HTT P42858 1/20 0.53
KMT2A Q03164 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
IGF1R P08069 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350274 0.86 EPHX2 (0.64) EPHX2STING1P2RY1NPC1RAB9A
SCHEMBL4345723 0.83 EPHX2 (0.64) EPHX2STING1P2RY1NPC1RAB9A
SCHEMBL4347461 0.83 NPC1 (0.59) NPC1RAB9APKMNFKB1NFKB2
SCHEMBL4341770 0.82 EPHX2 (0.63) EPHX2STING1NPC1RAB9ASMN1; SMN2
SCHEMBL11555827 0.81 EPHX2 (1.00) EPHX2STING1NPC1RAB9AFAAH
SCHEMBL4346994 0.81 EPHX2 (0.61) EPHX2STING1P2RY1NPC1RAB9A
SCHEMBL4349998 0.81 EPHX2 (0.73) EPHX2STING1P2RY1NPC1RAB9A
SCHEMBL4348999 0.80 KMT2A (0.70) EPHX2NPC1RAB9APKMNFKB1
SCHEMBL4346986 0.79 NPC1 (0.56) NPC1RAB9ASMN1; SMN2MEN1MAPT
SCHEMBL2872598 0.78 EPHX2 (0.69) EPHX2STING1P2RY1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 EPHX2 769/4885STING1 4861/4885P2RY1 3208/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 EPHX2 627/4885STING1 4863/4885P2RY1 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.